Vol 59, No 9 (2003)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

Myocardial infarction in patients aged less than 40 years. Frequency of BclI polymorphism in the fibrinogen β-chain gene and plasma fibrinogen

Krzysztof Lewandowski, Piotr Kwaśnikowski, Waldemar Elikowski, Krystyna Zawilska
Kardiol Pol 2003;59(9):209-211.
Vol 59, No 9 (2003)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Background: Several polymorphisms in the genes encoding for three separate chains of fibrinogen have been described. Some of them (Hae III and B854) are associated with elevated fibrinogen plasma level.
Aim: To determine the frequency of BclI polymorphism in the fibrinogen β-chain gene (BclI βFb) in young survivors of myocardial infraction (MI) and to assess the relationship between allele status, plasma fibrinogen concentration and the number of affected coronary arteries.
Methods: The study group consisted of 99 male patients (mean age 43.5, range 29-49 years) with premature coronary artery disease (CAD) diagnosed by coronary angiography who had MI in the mean age of 37.4±3.2 years. The control group involved 78 age- and gender-matched healthy volunteers. DNA was extracted from peripheral blood leukocytes using standard methods. Fibrinogen blood concentration was determined using biuretic method. The BclI polymorphism in the fibrinogen β-chain gene was investigated using polymerase chain reaction (PCR).
Results: Obesity was found in 15%, smoking - in 89%, hypertension - in 21%, diabetes - in 14% and hyperlipidemia - in 86% of MI patients. A family history of MI was present in 50% of patients. Coronary angiography revealed single-vessel disease in 34%, two-vessel disease in 36%, and three-vessel disease in 16% of patients. In two patients coronary angiography was normal. The frequency of BclI polymorphism of the β-fibrinogen gene was significantly higher in MI patients than in controls (40.4% vs 29.5%, p<0.01). Moreover, in MI patients carrying the mutant allele a higher concentration of blood fibrinogen was found in comparison to patients without this anomaly (3.87 vs 3.55 g/L, p=0.05). There was no evidence of an association between the number of affected coronary arteries and polymorphism of BclI βFbg gene status. However, all patients carrying BclI polymorphism of βFbg gene had abnormal coronary angiography, contrary to patients without any defect.
Conclusions: 1. Polymorphism of BclI βFbg gene is associated with an increased fibrinogen plasma level. 2. There is no association between BclI polymorphism of βFbg gene and the number of affected coronary arteries. This may confirm the hypothesis of multi-factorial aetiology of CAD in young patients suffering MI.

Abstract

Background: Several polymorphisms in the genes encoding for three separate chains of fibrinogen have been described. Some of them (Hae III and B854) are associated with elevated fibrinogen plasma level.
Aim: To determine the frequency of BclI polymorphism in the fibrinogen β-chain gene (BclI βFb) in young survivors of myocardial infraction (MI) and to assess the relationship between allele status, plasma fibrinogen concentration and the number of affected coronary arteries.
Methods: The study group consisted of 99 male patients (mean age 43.5, range 29-49 years) with premature coronary artery disease (CAD) diagnosed by coronary angiography who had MI in the mean age of 37.4±3.2 years. The control group involved 78 age- and gender-matched healthy volunteers. DNA was extracted from peripheral blood leukocytes using standard methods. Fibrinogen blood concentration was determined using biuretic method. The BclI polymorphism in the fibrinogen β-chain gene was investigated using polymerase chain reaction (PCR).
Results: Obesity was found in 15%, smoking - in 89%, hypertension - in 21%, diabetes - in 14% and hyperlipidemia - in 86% of MI patients. A family history of MI was present in 50% of patients. Coronary angiography revealed single-vessel disease in 34%, two-vessel disease in 36%, and three-vessel disease in 16% of patients. In two patients coronary angiography was normal. The frequency of BclI polymorphism of the β-fibrinogen gene was significantly higher in MI patients than in controls (40.4% vs 29.5%, p<0.01). Moreover, in MI patients carrying the mutant allele a higher concentration of blood fibrinogen was found in comparison to patients without this anomaly (3.87 vs 3.55 g/L, p=0.05). There was no evidence of an association between the number of affected coronary arteries and polymorphism of BclI βFbg gene status. However, all patients carrying BclI polymorphism of βFbg gene had abnormal coronary angiography, contrary to patients without any defect.
Conclusions: 1. Polymorphism of BclI βFbg gene is associated with an increased fibrinogen plasma level. 2. There is no association between BclI polymorphism of βFbg gene and the number of affected coronary arteries. This may confirm the hypothesis of multi-factorial aetiology of CAD in young patients suffering MI.
Get Citation

Keywords

myocardial infarction - bcli polymorphism of fibrinogen chain gene - fibrinogen

About this article
Title

Myocardial infarction in patients aged less than 40 years. Frequency of BclI polymorphism in the fibrinogen β-chain gene and plasma fibrinogen

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 59, No 9 (2003)

Pages

209-211

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2003;59(9):209-211.

Keywords

myocardial infarction - bcli polymorphism of fibrinogen chain gene - fibrinogen

Authors

Krzysztof Lewandowski
Piotr Kwaśnikowski
Waldemar Elikowski
Krystyna Zawilska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl